Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer-Reference-Cited by-同舟云学术

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Published:2019-09-01 Issue:9 Volume:5 Page:1310
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Simonaggio Audrey¹,Michot Jean Marie¹²,Voisin Anne Laure³,Le Pavec Jérome⁴,Collins Michael⁵⁶,Lallart Audrey³,Cengizalp Geoffray³,Vozy Aurore¹,Laparra Ariane¹,Varga Andréa¹,Hollebecque Antoine¹,Champiat Stéphane¹,Marabelle Aurélien¹,Massard Christophe¹,Lambotte Olivier²⁷⁸⁹

Affiliation:

1. Department of Drug Development (DITEP), Gustave Roussy, Villejuif, France

2. Department of Internal Medicine and Clinical Immunology, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, Le Kremlin-Bicêtre, France

3. Pharmacovigilance Unit, Gustave Roussy, Villejuif, France

4. Department of Thoracic and Cardiovascular Surgery and Heart and Lung Transplantation, Hôpital Marie Lannelongue, Le Plessis Robinson, France

5. Gastroenterology Unit, Université Paris-Sud, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, Le Kremlin-Bicêtre, France

6. Inserm U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif, France

7. Inserm U1184, Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre, France

8. Université Paris-Sud, UMR 1184, Le Kremlin-Bicêtre, France

9. CEA, DSV/iMETI, Infectious Disease Models and Innovative Therapies, Fontenay-aux-Roses, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2735330/jamaoncology_simonaggio_2019_oi_190027.pdf

Reference27 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma.;Hodi;N Engl J Med,2010

2. Nivolumab in previously untreated melanoma without BRAF mutation.;Robert;N Engl J Med,2015

3. Overall survival with combined nivolumab and ipilimumab in advanced melanoma.;Wolchok;N Engl J Med,2017

4. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.;Eggermont;N Engl J Med,2016

5. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.;Weber;N Engl J Med,2017

Cited by 295 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study;Oral Oncology;2024-11

2. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

3. Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study;Annals of Oncology;2024-09

4. Peripheral nervous system immune-related adverse events due to checkpoint inhibition;Nature Reviews Neurology;2024-08-09

5. Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias;Cancer Research and Treatment;2024-07-15